The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Coordination chemistry reviews

• Publication date

  2009-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.CCR.2009.01.032PMID 20047011PMCID PMC2675785
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular targeted therapies for breast cancer treatment

  2008cited by this paper
• Bioenergetic differences selectively sensitize tumorigenic liver progenitor cells to a new gold(I) compound.

  2008cited by this paper
• A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.

  2008cited by this paper
• A Phase II Study of Single Agent Bortezomib in Patients with Metastatic Breast Cancer: A Single Institution Experience

  2007cited by this paper
• A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria.

  2007cited by this paper
• Auranofin blocks interleukin‐6 signalling by inhibiting phosphorylation of JAK1 and STAT3

  2007cited by this paper
• Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.

  2007cited by this paper
• Gold(I) chloride adducts of 1,3-bis(di-2-pyridylphosphino)propane: synthesis, structural studies and antitumour activity.

  2007cited by this paper
• Antiproliferative and apoptotic effects of two new gold(III) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells in vitro

  2007cited by this paper
• Non Platinum Metal Complexes as Anti‐cancer Drugs

  2007cited by this paper
• Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway.

  2007cited by this paper
• Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds

  2006cited by this paper
• Gold coordination complexes as anticancer agents.

  2006cited by this paper
• Inhibition of lysosomal cysteine proteases by a series of Au(I) complexes: a detailed mechanistic investigation.

  2006cited by this paper
• The Discovery and Development of Cisplatin

  2006cited by this paper
• The proteasome as a potential target for novel anticancer drugs and chemosensitizers.

  2006cited by this paper
• DNA binding properties of novel cytotoxic gold(III) complexes of terpyridine ligands: the impact of steric and electrostatic effects

  2006cited by this paper
• Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.

  2006cited by this paper
• Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties.

  2006cited by this paper
• United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy

  2006cited by this paper
• Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner

  2006cited by this paper
• A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.

  2006cited by this paper
• Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.

  2006cited by this paper
• Proteomic characterization of the cytotoxic mechanism of gold (III) porphyrin 1a, a potential anticancer drug

  2006cited by this paper
• Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity.

  2005cited by this paper
• p53 Proteasomal Degradation: Poly-Ubiquitination is Not the Whole Story

  2005cited by this paper
• The ubiquitin proteasome pathway from bench to bedside.

  2005cited by this paper
• Gold(III) Porphyrin 1a Induced Apoptosis by Mitochondrial Death Pathways Related to Reactive Oxygen Species

  2005cited by this paper
• Synthesis, characterization, and comparative in vitro cytotoxicity studies of platinum(II), palladium(II), and gold(III) methylsarcosinedithiocarbamate complexes.

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells

  2005cited by this paper
• GoldIII porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species.

  2005cited by this paper
• Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies

  2005cited by this paper
• Hydrolysis process of the second generation platinum-based anticancer drug cis-amminedichlorocyclohexylamineplatinum(II).

  2005cited by this paper
• Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c.

  2004cited by this paper
• Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

  2004cited by this paper
• The changing global patterns of female breast cancer incidence and mortality

  2004cited by this paper
• A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

  2004cited by this paper
• Repeat Sequence of Epstein-Barr Virus-encoded Nuclear Antigen 1 Protein Interrupts Proteasome Substrate Processing*

  2004cited by this paper
• Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells.

  2004cited by this paper
• Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro

  2004cited by this paper
• Complexes of dichloro[2-(dimethylaminomethyl)phenyl-C1,N]gold(III), [Au(damp-C1,N)Cl2], with formylferrocene thiosemicarbazones: synthesis, structure and cytotoxicity.

  2004cited by this paper
• Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.

  2004cited by this paper
• Ubiquitin Conjugation Is Not Required for the Degradation of Oxidized Proteins by Proteasome*

  2003cited by this paper
• Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib.

  2003cited by this paper
• Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

  2003cited by this paper
• The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

  2003cited by this paper
• Phosphinegold(I) Thiolates – Pharmacological Use and Potential

  2003cited by this paper
• Reactions of gold(III) complexes with serum albumin.

  2003cited by this paper
• Gold(III) Compounds as New Family of Anticancer Drugs

  2003cited by this paper
• The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

  2003cited by this paper
• Potential for proteasome inhibition in the treatment of cancer.

  2003cited by this paper
• Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• Docking studies and model development of tea polyphenol proteasome inhibitors: Applications to rational drug design

  2003cited by this paper
• Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review.

  2003cited by this paper
• Bortezomib (millennium pharmaceuticals).

  2002cited by this paper
• The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer

  2002cited by this paper
• Functional repression of estrogen receptor a by arsenic trioxide in human breast cancer cells.

  2002cited by this paper
• Proteolysis, free radicals, and aging.

  2002cited by this paper
• The proteasome: a novel target for cancer chemotherapy

  2002cited by this paper
• Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria

  2002cited by this paper
• Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.

  2002cited by this paper
• Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties.

  2002cited by this paper
• Recent progress in the development of anticancer agents.

  2002cited by this paper
• Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

  2002cited by this paper
• Immunomodulatory Effect of Gold Sodium Thiomalate on Murine Acquired Immunodeficiency Syndrome

  2001cited by this paper
• Toward a novel metal-based chemotherapy against tropical diseases. 6. Synthesis and characterization of new copper(II) and gold(I) clotrimazole and ketoconazole complexes and evaluation of their activity against Trypanosoma cruzi.

  2001cited by this paper
• Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

  2001cited by this paper
• The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI

  2001cited by this paper
• Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex.

  2001cited by this paper
• Proteasome inhibitors: from research tools to drug candidates.

  2001cited by this paper
• Photodynamic Therapy-induced Apoptosis in Epidermoid Carcinoma Cells

  2001cited by this paper
• Proteasomes are a target of the anti-tumour drug vinblastine.

  2001cited by this paper
• Estrogen and rapamycin effects on cell cycle progression in T47D breast cancer cells

  2001cited by this paper
• CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice.

  2001cited by this paper
• Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and Bax expression, and induces G1 arrest and apoptosis.

  2001cited by this paper
• Estimating the world cancer burden: Globocan 2000

  2001cited by this paper
• Proteasomes are a target of the anti-tumour drug vinblastine

  2001cited by this paper
• Effect of Glutathione Depletion on Antitumor Drug Toxicity (Apoptosis and Necrosis) in U-937 Human Promonocytic Cells

  2001cited by this paper
• China’s ancient gold drugs

  2001cited by this paper
• Structural basis for the activation of 20S proteasomes by 11S regulators

  2000cited by this paper
• Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase.

  2000cited by this paper
• Structural Basis for the Activation of Proteasomes by 11S Regulators

  2000cited by this paper
• The proteasome activator 11 S REG (PA28) and class I antigen presentation.

  2000cited by this paper
• Hybrid Proteasomes

  2000cited by this paper
• Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.

  2000cited by this paper
• Hybrid proteasomes. Induction by interferon-gamma and contribution to ATP-dependent proteolysis.

  2000cited by this paper
• Proteasome inhibition measurements: clinical application.

  2000cited by this paper
• Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds.

  2000cited by this paper
• Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression.

  2000cited by this paper
• Ubiquitin‐mediated proteolysis: biological regulation via destruction

  2000cited by this paper
• Inhibition of NF-κB Activation by Arsenite through Reaction with a Critical Cysteine in the Activation Loop of IκB Kinase*

  2000cited by this paper
• A Screening Strategy for Metal Antitumor Agents as Exemplified by Gold(III) Complexes

  1999cited by this paper
• Gold(III)-induced oxidation of glycine†

  1999cited by this paper
• Proteasome inhibitors: a novel class of potent and effective antitumor agents.

  1999cited by this paper
• Proteasomes in apoptosis: villains or guardians?

  1999cited by this paper
• Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase.

  1999cited by this paper
• Global cancer statistics

  1999cited by this paper
• The role of the ubiquitin-proteasome pathway in apoptosis

  1999cited by this paper

• Advancements in the Bio-efficacy of Gold-based Complexes: A Comprehensive Review of Synthetic Approach and Therapeutic Potential

  2026cites this paper
• Combining Gold and Selenium as Emerging Bioactive Compounds: From Synthesis to Therapeutic Potential

  2026cites this paper
• Advances in the Potential of Quinoline‐Derived Metal Complexes as Antimalarial Agents: A Review

  2025cites this paper
• Multimodal anticancer potential of newly synthesized palladium(II), platinum(II), and gold(III) complexes with 2-(Thiazol-2-yl)pyridine-4,5-dicarboxylate dimethyl ester.

  2025cites this paper
• Gold Complexes and Their Molecular Targets in Colorectal Cancer

  2024cites this paper
• Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides—Current Developments in Structure-Activity Relationship

  2024cites this paper
• Recent advancements in nanomaterial-mediated ferroptosis-induced cancer therapy: Importance of molecular dynamics and novel strategies.

  2024cites this paper
• Chiral Au(III) chelates exhibit unique NCI-60 cytotoxicity profiles and interactions with human serum albumin.

  2024cites this paper
• Next Generation Gold Drugs and Probes: Chemistry and Biomedical Applications.

  2023cites this paper
• Harnessing the power of gold: advancements in anticancer gold complexes and their functionalized nanoparticles.

  2023cites this paper
• Addressing the gaps in homeostatic mechanisms of copper and copper dithiocarbamate complexes in cancer therapy: a shift from classical platinum-drug mechanisms.

  2023cites this paper
• Pt(IV) and Au(III) complexes with tridentate-benzothiazole based ligand: synthesis, characterization, biological applications (antibacterial, antifungal, antioxidant, anticancer and molecular docking) and DFT calculation

  2023cites this paper
• Anticancer activity and DNA interaction of bis(pyridyl)allene-derived metal complexes

  2023cites this paper
• Genome-wide CRISPR Screen Reveal Targets of Chiral Gold(I) Anticancer Compound in Mammalian Cells

  2022cites this paper
• Thermoresponsive Zinc TetraPhenylPorphyrin Photosensitizer/Dextran Graft Poly(N-IsoPropylAcrylAmide) Copolymer/Au Nanoparticles Hybrid Nanosystem: Potential for Photodynamic Therapy Applications

  2022cites this paper
• Synthesis, spectral characterization and biological activities of Ag(I), Pt(IV) and Au(III) complexes with novel azo dye ligand (N, N, O) derived from 2-amino-6-methoxy benzothiazole

  2022cites this paper
• Gold(III)-P-chirogenic complex induces mitochondrial dysfunction in triple-negative breast cancer

  2022cites this paper
• Water‐Soluble Gold(III)–Metformin Complex Alters Mitochondrial Bioenergetics in Breast Cancer Cells

  2021cites this paper
• Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer.

  2021cites this paper
• Amino-acid interactions with the Au(111) surface: adsorption, band alignment, and interfacial electronic coupling.

  2021cites this paper
• Classes of Gold Complexes

  2021cites this paper
• Plasmonic enhancement of the antibacterial photodynamic efficiency of a zinc tetraphenylporphyrin photosensitizer/dextran graft polyacrylamide anionic copolymer/Au nanoparticles hybrid nanosystem

  2021cites this paper
• Metals and Metal Complexes for Medicinal Applications

  2021cites this paper
• Anticancer Activity and Apoptosis Induction of Gold(III) Complexes Containing 2,2′-Bipyridine-3,3′-dicarboxylic Acid and Dithiocarbamates

  2021cites this paper
• Ligand substituent effect on the cytotoxicity activity of two new copper(ii) complexes bearing 8-hydroxyquinoline derivatives: validated by MTT assay and apoptosis in MCF-7 cancer cell line (human breast cancer)

  2021cites this paper
• Gold(III) Complexes: An Overview on Their Kinetics, Interactions With DNA/BSA, Cytotoxic Activity, and Computational Calculations

  2020cites this paper
• Chemical approaches for the enhancement of porphyrin skeleton-based photodynamic therapy

  2020cites this paper
• ESI MS studies highlight the selective interaction of Auranofin with protein free thiols.

  2020cites this paper
• Density functional theory study of gold(III)-dithiocarbamate complexes with characteristic anticancer potentials.

  2020cites this paper
• Selective modification of alkyne-linked peptides and proteins by cyclometalated gold(III) (C^N) complex-mediated alkynylation.

  2020cites this paper
• Cyclometalated Gold(III) Complexes Bearing DACH Ligands.

  2019cites this paper
• Reactivity of Gold(I) Monocarbene Complexes with Protein Targets: A Theoretical Study

  2019cites this paper
• Advances in diphosphine ligand-containing gold complexes as anticancer agents

  2019cites this paper
• Proteasome vs Thioredoxin reductase competition as possible biological targets in antitumor mixed thiolate- dithiocarbamate gold(III) complexes

  2019cites this paper
• Muscle Growth, Repair, and Preservation

  2019cites this paper
• Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.

  2019cites this paper
• Dinuclear cobalt and nickel complexes of a mercaptoacetic acid substituted 1,2,4-triazole ligand: syntheses, structures and urease inhibitory studies.

  2019cites this paper
• Comparative study of the antitumoral activity of phosphine-thiosemicarbazone gold(I) complexes obtained by different methodologies.

  2019cites this paper
• Nanomaterial-induced ferroptosis for cancer specific therapy

  2019cites this paper
• Synthesis of terpyridine-containing Pd(II) complexes and evaluation of their catalytic activity

  2019cites this paper
• Synthesis and Characterization of NHC * s Gold ( I ) Complexes with Biological Molecules in the Coordination Sphere

  2019cites this paper
• Gold(I/III)-Phosphine Complexes as Potent Antiproliferative Agents

  2019cites this paper
• DFT Study of the Structural and Electronic Properties of Selected Organogold(III) Compounds with Characteristic Anticancer Activity

  2019cites this paper
• Pyridylbenzimidazole-Based Gold(III) Complexes: Lysozyme Metalation, DNA Binding Studies, and Biological Activity

  2019cites this paper
• Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.

  2018cites this paper
• In vitro and in vivo studies of gold(I) azolate/phosphane complexes for the treatment of basal like breast cancer.

  2018cites this paper
• Interaction of Au(iii) and Pt(ii) complexes with Na/K-ATPase: experimental and theoretical study of reaction stoichiometry and binding sites.

  2018cites this paper
• Proteasome versus Thioredoxin Reductase Competition as Possible Biological Targets in Antitumor Mixed Thiolate-Dithiocarbamate Gold(III) Complexes.

  2018cites this paper
• Quinoline based Pd(II) complexes: Synthesis, characterization and evaluation of DNA/protein binding, molecular docking and in vitro anticancer activity

  2018cites this paper
• Water-soluble gold(III) complexes with N-donor ligands as potential immunomodulatory and antibiofilm agents

  2018cites this paper
• Spectroscopy, electrochemistry and antiproliferative properties of Au(iii), Pt(ii) and Cu(ii) complexes bearing modified 2,2':6',2''-terpyridine ligands.

  2018cites this paper
• Synthesis of Copper (II) Complexes With Antitumor Activity

  2017cites this paper
• Novel gold(I) complexes with 5-phenyl-1,3,4-oxadiazole-2-thione and phosphine as potential anticancer and antileishmanial agents.

  2017cites this paper
• Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents

  2017cites this paper
• Synthesis of novel macrocyclic Schiff's-base and its complexes having N2O2 group of donor atoms. Characterization and anticancer screening are studied

  2017cites this paper
• Anticancer Agents Beyond Cisplatin

  2017cites this paper
• Cytotoxic gold(iii) complexes incorporating a 2,2':6',2''-terpyridine ligand framework - the impact of the substituent in the 4'-position of a terpy ring.

  2017cites this paper
• Amphiphilic oligo(ethylene glycol)- and poly(ethyleneoxide)-block-poly(propylene oxide)-block-poly-(ethylene oxide)-containing cyclometalated alkynylgold(III) complexes: From basic photophysics to self-assembly and stimuli-responsive properties

  2017cites this paper
• WITHDRAWN: Synthesis, DNA/protein binding, molecular docking and in vitro anticancer activity of quinoline based palladium(II) complexes

  2017cites this paper
• Gold(I) complexes with aryl-thiosemicarbazones: Molecular modeling, synthesis, cytotoxicity and TrxR inhibition

  2017cites this paper
• Synthesis of gold(iii) ←gold(i)‒NHC through disproportionation: the role of gold(i)‒NHC in the induction of apoptosis in HepG2 cells

  2016cites this paper
• Uncommon and Emissive {[Au2(C3H6NS2)2][Au(C3H6NS2)2]2(PF6)2} Mixed Au+ and Au3+ Pseudotetranuclear Crystalline Compound: Synthesis, Structural Characterization, and Optical Properties.

  2016cites this paper
• Synthesis, characterization and pharmacological studies of copper complexes of flavone derivatives as potential anti-tuberculosis agents.

  2016cites this paper
• Size, shape and surface chemistry of nano-gold dictate its cellular interactions, uptake and toxicity

  2016cites this paper
• Metal Based Compounds, Modulators of Na, K-ATPase with Anticancer Activity

  2016cites this paper
• X-ray characterization and in vitro biological evaluation of 1-(4-amidophenyl)-3-(4-acetylphenyl)triazene and the gold(I) triazenide complex {Au(I)[RPhNNNPhR′][PPh3]} [R = (CO)NH2, R′ = (CO)CH3]

  2016cites this paper
• Crystal structure and cytotoxic activities of a bis(pyrrolyl-imine) gold(III) complex

  2016cites this paper
• Synthesis, structural characterization, electrochemical behavior and anticancer activity of gold(III) complexes of meso-1,2-di(1-naphthyl)-1,2-diaminoethane and tetraphenylporphyrin

  2016cites this paper
• Nanostructured materials functionalized with metal complexes: In search of alternatives for administering anticancer metallodrugs

  2016cites this paper
• Evaluation of the cell cytotoxicity and DNA/BSA binding and cleavage activity of some dioxidovanadium(V) complexes containing aroylhydrazones.

  2015cites this paper
• Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds

  2015cites this paper
• Synthesis, characterization and theoretical calculations of (1,2-diaminocyclohexane)(1,3-diaminopropane)gold(III) chloride complexes: in vitro cytotoxic evaluations against human cancer cell lines

  2015cites this paper
• Synthesis and Anticancer Activity of Water Soluble Porphyrin APPROVED BY SUPERVISING COMMITTEE:

  2015cites this paper
• Coordination behavior of new bis Schiff base ligand derived from 2-furan carboxaldehyde and propane-1,3-diamine. Spectroscopic, thermal, anticancer and antibacterial activity studies.

  2015cites this paper
• Synthesis and anti-cancer activities of a water soluble gold(III) porphyrin.

  2015cites this paper
• Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics.

  2015cites this paper
• In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH2Ph)]Br.

  2015cites this paper
• Luminescent Behavior of Ru(II) Polypyridyl Morpholine Complexes, Synthesis, Characterization, DNA, Protein Binding, Sensor Effect of Ions/Solvents and Docking Studies

  2015cites this paper
• Synthesis, structural characterization, molecular docking, and urease inhibition studies of dinuclear cobalt(II) complexes derived from 3,5-bis(pyridin-2-yl)-4-amino-1,2,4-triazole

  2014cites this paper
• Supramolecular dithiocarbamatogold(III) complex a potential DNA binder and antioxidant agent

  2014cites this paper
• Therapeutic Gold Compounds

  2014cites this paper
• Gold(I) Complexes of 9-Deazahypoxanthine as Selective Antitumor and Anti-Inflammatory Agents

  2014cites this paper
• Proteasome inhibitor patents (2010 – present)

  2014cites this paper
• Diverse in vitro and in vivo anti-inflammatory effects of trichlorido-gold(III) complexes with N6-benzyladenine derivatives.

  2014cites this paper
• Inhibition of Na(+)/K(+)-ATPase and cytotoxicity of a few selected gold(III) complexes.

  2014cites this paper
• Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth

  2014cites this paper
• Synthesis, characterization, cytotoxicity and antibacterial activity of an anthracenyl-linked bis(pyrazolyl)methane ligand and its zinc(II) complexes.

  2014cites this paper
• Synthesis, characterization, and antitumor activity of unusual pseudo five coordinate gold(III) complexes: distinct cytotoxic mechanism or expensive ligand delivery systems?

  2014cites this paper
• Synthesis and biological assays on cancer cells of dinuclear gold complexes with novel functionalised di(N-heterocyclic carbene) ligands.

  2014cites this paper
• Synthesis, structure, and properties of Cd(II) complexes generated from 2-phenylquinoline derivatives

  2014cites this paper
• Gold(III) complexes in medicinal chemistry.

  2014cites this paper
• Synthesis and cytotoxic activity of gold(I) complexes containing phosphines and 3-benzyl-1,3-thiazolidine-2-thione or 5-phenyl-1,3,4-oxadiazole-2-thione as ligands

  2014cites this paper
• A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases

  2014cites this paper
• Neziskové léky: Aktivita komplexu disulfiramu (antabusu) s mědí proti buněčné linii odvozené od osteosarkomu

  2013cites this paper
• Comparison of the intracellular behavior of gold (Au) and indium (In) in testicle after their parenteral administration.

  2013cites this paper
• Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer.

  2013cites this paper
• Novel tetranuclear triarylantimony(V) complexes with (±)-mandelic acid ligands: synthesis, characterization, in vitro cytotoxicity and DNA binding properties.

  2013cites this paper
• Halogenated Gold(III) Complexes Containing 4-Cyanopyridine: Synthesis, Characterization, and Crystal Structure

  2013cites this paper
• S-Propargylthiopyridine Phosphane Derivatives As Anticancer Agents: Characterization and Antitumor Activity

  2013cites this paper
• Synthesis and characterization of novel gold(III) complexes with polydentate N-donor ligands based on the pyridine and triazole heterocycles

  2013cites this paper